Recent advances in the use of serological bone formation markers to monitor callus development and fracture healing

Critical Reviews in Eukaryotic Gene Expression

Volumn 20, Issue 2, 2010, Pages 105-127

  Coulibaly, Marlon O ^a   Sietsema, Debra L ^b,c,d   Burgers, Travis A ^c   Mason, Jim ^c   Williams, Bart O ^c   Jones, Clifford B ^b,c,d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Orthopaedic Associates of Michigan   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Bone metabolic marker; Bone turnover marker; Collagen synthesis; Fracture healing; Non union; Procollagen type I amino terminal propeptide (PINP)

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; OSTEOCALCIN; PROCOLLAGEN TYPE I AMINO TERMINAL PROPEPTIDE; PROCOLLAGEN TYPE I C TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTICLE; BLOOD LEVEL; BONE METABOLISM; BONE REGENERATION; BONE TURNOVER; CALLUS; COLLAGEN SYNTHESIS; EARLY DIAGNOSIS; ENCHONDRAL OSSIFICATION; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; SEROLOGY; BLOOD; BONE DEVELOPMENT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; BONY CALLUS; FRACTURE HEALING; HUMANS; OSTEOGENESIS; OSTEOPOROSIS; PROGNOSIS;

EID: 79952278027     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v20.i2.20     Document Type: Article

References (176)

1. Nawar EW, Niska RW, Xu J. National Hospital Ambulatory Medical Care Survey: 2005 emergency department summary. Adv Data. 2007;(386):1-32.
2. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Community Health. 1990;44(3):241-5.
3. Banks E, Reeves GK, Beral V, Balkwill A, Liu B, Roddam A, For the Million Women Study C. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLoS Med. 2009;6(11):e1000181.
4. Court-Brown CM, Caesar B. Epidemiology of adult fractures: A review. Injury. 2006;37(8):691-7.
5. Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem. 2003;88(5):873-84.
6. Nork SE. Fractures of the Shaft of the Femur. In: Bucholz RW, Heckman JD, Court-Brown CM, editors. Rockwood and Green's Fractures in Adults. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2006. p. 1845-914.
7. ®: summary of safety and effectiveness. Low-intensity pulsed ultrasound device for the noninvasive treatment of nonunions. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf/P900009S006b.pdf (published 2000 Feb 22; cited 2010 Oct 10).
8. Court-Brown CM, McQueen MM. Nonunions of the proximal humerus: their prevalence and functional outcome. J Trauma. 2008;64(6):1517-21.
9. Parker MJ, Raghavan R, Gurusamy K. Incidence of fracture-healing complications after femoral neck fractures. Clin Orthop Relat Res. 2007;458:175-9.
10. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000;82(5):655-8.
11. Society COT. Nonunion following intramedullary nailing of the femur with and without reaming. Results of a multicenter randomized clinical trial. J Bone Joint Surg Am. 2003;85-A(11):2093-6.
12. Phieffer LS, Goulet JA. Delayed unions of the tibia. Instr Course Lect. 2006;55:389-401.
13. Taitsman LA, Lynch JR, Agel J, Barei DP, Nork SE. Risk factors for femoral nonunion after femoral shaft fracture. J Trauma. 2009;67(6):1389-92.
14. Ly TV, Swiontkowski MF. Treatment of femoral neck fractures in young adults. J Bone Joint Surg Am. 2008;90(10):2254-66.
15. Yokoyama K, Itoman M, Uchino M, Fukushima K, Nitta H, Kojima Y. Immediate versus delayed intramedullary nailing for open fractures of the tibial shaft: A multivari-ate analysis of factors affecting deep infection and fracture healing. Indian J Orthop. 2008;42(4):410-9.
16. Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res. 1988;(232):210-6.
17. Foulk DA, Szabo RM. Diaphyseal humerus fractures: natural history and occurrence of nonunion. Orthopedics. 1995;18(4):333-5.
18. Lindsey RW, Blair SR. Closed tibial-shaft fractures: which ones benefit from surgical treatment? J Am Acad Orthop Surg. 1996;4(1):35-43.
19. Kyro A, Usenius JP, Aarnio M, Kunnamo I, Avikainen V. Are smokers a risk group for delayed healing of tibial shaft fractures? Ann Chir Gynaecol. 1993;82(4):254-62.
20. Adams CI, Keating JF, Court-Brown CM. Cigarette smoking and open tibial fractures. Injury. 2001;32(1):61-5.
21. Ueng SW, Chao EK, Lee SS, Shih CH. Augmentative plate fixation for the management of femoral nonunion after in-tramedullary nailing. J Trauma. 1997;43(4):640-4.
22. Whelan DB, Bhandari M, Stephen D, Kreder H, McKee MD, Zdero R, Schemitsch EH. Development of the radiographic union score for tibial fractures for the assessment of tibial fracture healing after intramedullary fixation. J Trauma. 2010;68(3):629-32.
23. Kuhlman JE, Fishman EK, Magid D, Scott WW Jr, Brooker AF, Siegelman SS. Fracture nonunion: CT assessment with multiplanar reconstruction. Radiology. 1988;167(2):483-8.
24. Webb LX, Winquist RA, Hansen ST. Intramedullary nailing and reaming for delayed union or nonunion of the femoral shaft. A report of 105 consecutive cases. Clin Orthop Relat Res. 1986;(212):133-41.
25. Wu CC. The effect of dynamization on slowing the healing of femur shaft fractures after interlocking nailing. J Trauma. 1997;43(2):263-7.
26. Weresh MJ, Hakanson R, Stover MD, Sims SH, Kellam JF, Bosse MJ. Failure of exchange reamed intramedullary nails for ununited femoral shaft fractures. J Orthop Trauma. 2000;14(5):335-8.
27. Patil S, Montgomery R. Management of complex tibial and femoral nonunion using the Ilizarov technique, and its cost implications. J Bone Joint Surg Br. 2006;88(7):928-32.
28. Dahabreh Z, Calori GM, Kanakaris NK, Nikolaou VS, Gi-annoudis P V. A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic pro-tein-7. Int Orthop. 2009;33(5):1407-14.
29. Ramachandran GN, Kartha G. Structure of collagen. Nature. 1954;174(4423):269-70.
30. Weiner S, Traub W, Wagner HD. Lamellar bone: structure-function relations. J Struct Biol. 1999;126(3):241-55.
31. Traub W, Piez KA. The chemistry and structure of collagen. Adv Protein Chem. 1971;25:243-352.
32. Helseth DL Jr, Veis A. Collagen self-assembly in vitro. Differentiating specific telopeptide-dependent interactions using selective enzyme modification and the addition of free amino telopeptide. J Biol Chem. 1981;256(14):7118-28.
33. Bornstein P, Ehrlich HP, Wyke AW. Procollagen: conversion of the precursor to collagen by a neutral protease. Science. 1972;175(21):544-6.
34. Bornstein P, Von der Mark K, Wyke AW, Ehrlich HP, Mon-son JM. Characterization of the pro- 1 chain of procollagen. J Biol Chem. 1972;247(9):2808-13.
35. Fessler LI, Morris NP, Fessler JH. Procollagen: biological scission of amino and carboxyl extension peptides. Proc Natl Acad Sci U S A. 1975;72(12):4905-9.
36. Miyahara M, Hayashi K, Berger J, Tanzawa K, Njieha FK, Trelstad RL, Prockop DJ. Formation of collagen fibrils by enzymic cleavage of precursors of type I collagen in vitro. J Biol Chem. 1984;259(15):9891-8.
37. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA. The biosynthesis of collagen and its disorders (second of two parts). N Engl J Med. 1979;301(2):77-85.
38. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA. The biosynthesis of collagen and its disorders (first of two parts). N Engl J Med. 1979;301(1):13-23.
39. Hojima Y, Morgelin MM, Engel J, Boutillon MM, van der Rest M, McKenzie J, Chen GC, Rafi N, Romanic AM, Prockop DJ. Characterization of type I procollagen N-proteinase from fetal bovine tendon and skin. Purification of the 500-kilodalton form of the enzyme from bovine tendon. J Biol Chem. 1994;269(15):11381-90.
40. Prockop DJ, Sieron AL, Li SW. Procollagen N-proteinase and procollagen C-proteinase. Two unusual metalloprotei-nases that are essential for procollagen processing probably have important roles in development and cell signaling. Matrix Biol. 1998;16(7):399-408.
41. Weiner S, Traub W. Bone structure: from angstroms to microns. FASEB J. 1992;6(3):879-85.
42. Hodge AJ. Molecular models illustrating the possible distributions of 'holes' in simple systematically staggered arrays of type I collagen molecules in native-type fibrils. Connect Tissue Res. 1989;21(1-4):137-47.
43. Otsubo K, Katz EP, Mechanic GL, Yamauchi M. Cross-linking connectivity in bone collagen fibrils: the COOH-terminal locus of free aldehyde. Biochemistry. 1992;31(2):396-402.
44. Robins SP. Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. Bio-chem J. 1983;215(1):167-73.
45. Gunja-Smith Z, Boucek RJ. Collagen cross-linking compounds in human urine. Biochem J. 1981;197(3):759-62.
46. Ge G, Seo NS, Liang X, Hopkins DR, Hook M, Greenspan DS. Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem. 2004;279(40):41626-33.
47. Veis A, Anesey J, Yuan L, Levy SJ. Evidence for an ami-no-terminal extension in high-molecular-weight colla-gens from mature bovine skin. Proc Natl Acad Sci U S A. 1973;70(5):1464-7.
48. Bornstein P, Walsh V, Tullis J, Stainbrook E, Bateman JF, Hormuzdi SG. The globular domain of the proalpha 1(I) N-propeptide is not required for secretion, processing by procollagen N-proteinase, or fibrillogenesis of type I collagen in mice. J Biol Chem. 2002;277(4):2605-13.
49. Fisher LW, Robey PG, Tuross N, Otsuka AS, Tepen DA, Esch FS, Shimasaki S, Termine JD. The Mr 24,000 phos-phoprotein from developing bone is the NH2-terminal propeptide of the alpha 1 chain of type I collagen. J Biol Chem. 1987;262(28):13457-63.
50. Cabral WA, Makareeva E, Colige A, Letocha AD, Ty JM, Yeowell HN, Pals G, Leikin S, Marini JC. Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing. J Biol Chem. 2005;280(19):19259-69.
51. Pope FM, Burrows NP. Ehlers-Danlos syndrome has varied molecular mechanisms. J Med Genet. 1997;34(5):400-10.
52. Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. 2010;25(6):1367-74.
53. Meyer RA, Jr., Desai BR, Heiner DE, Fiechtl J, Porter S, Meyer MH. Young, adult, and old rats have similar changes in mRNA expression of many skeletal genes after fracture despite delayed healing with age. J Orthop Res. 2006;24(10):1933-44.
54. Ferguson CM, Miclau T, Hu D, Alpern E, Helms JA. Common molecular pathways in skeletal morphogenesis and repair. Ann N Y Acad Sci. 1998;857:33-42.
55. Kaplan FS, Hayes WC, Keaveny TM, Boskey A, Einhorn TA, Iannotti JP. Form and function of bone. In: Simon SS, editor. Orthopaedic basic science. Rosemont (IL): Amer-can Academy of Orthopaedic Surgeons; 1994. p. 127-84.
56. Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bet-tica P, Baylink DJ. Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem. 1993;39(11 Pt 1):2254-8.
57. Buckwalter JA, Einhorn TA, Marsh JL. Bone and joint healing. In: Bucholz RW, Heckman JD, Court-Brown CM, editors. Rockwood and Green's fractures in adults. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2006. p. 297-312.
58. Reddi AH, Gay R, Gay S, Miller EJ. Transitions in collagen types during matrix-induced cartilage, bone, and bone marrow formation. Proc Natl Acad Sci U S A. 1977;74(12):5589-92.
59. Page M, Hogg J, Ashhurst DE. The effects of mechanical stability on the macromolecules of the connective tissue matrices produced during fracture healing. I. The colla-gens. Histochem J. 1986;18(5):251-65.
60. Gerstenfeld LC, Alkhiary YM, Krall EA, Nicholls FH, Stapleton SN, Fitch JL, Bauer M, Kayal R, Graves DT, Jepsen KJ, Einhorn TA. Three-dimensional reconstruction of fracture callus morphogenesis. J Histochem Cytochem. 2006;54(11):1215-28.
61. McKibbin B. The biology of fracture healing in long bones. J Bone Joint Surg Br. 1978;60-B(2):150-62.
62. Reddi AH, Anderson WA. Collagenous bone matrix-induced endochondral ossification hemopoiesis. J Cell Biol. 1976;69(3):557-72.
63. Lane JM, Suda M, von der Mark K, Timpl R. Im-munofluorescent localization of structural collagen types in endochondral fracture repair. J Orthop Res. 1986;4(3):318-29.
64. Sandberg M, Aro H, Multimaki P, Aho H, Vuorio E. In situ localization of collagen production by chondrocytes and osteoblasts in fracture callus. J Bone Joint Surg Am. 1989;71(1):69-77.
65. Multimaki P, Aro H, Vuorio E. Differential expression of fibrillar collagen genes during callus formation. Biochem Biophys Res Commun. 1987;142(2):536-41.
66. Chiba S, Okada K, Lee K, Segre GV, Neer RM. Molecular analysis of defect healing in rat diaphyseal bone. J Vet Med Sci. 2001;63(6):603-8.
67. Yamagiwa H, Tokunaga K, Hayami T, Hatano H, Uchida M, Endo N, Takahashi HE. Expression of metalloprotein-ase-13 (Collagenase-3) is induced during fracture healing in mice. Bone. 1999;25(2):197-203.
68. Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA. Expression of osteoprote-gerin, receptor activator of NF-kappaB ligand (osteoprote- gerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res. 2001;16(6):1004-14.
69. Hiltunen A, Aro HT, Vuorio E. Regulation of extracellular matrix genes during fracture healing in mice. Clin Orthop Relat Res. 1993;(297):23-7.
70. Riikonen T, Westermarck J, Koivisto L, Broberg A, Kahari VM, Heino J. Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(I) gene expression. J Biol Chem. 1995;270(22):13548-52.
71. Riikonen T, Koivisto L, Vihinen P, Heino J. Transforming growth factor-beta regulates collagen gel contraction by increasing alpha 2 beta 1 integrin expression in osteogenic cells. J Biol Chem. 1995;270(1):376-82.
72. Ekholm E, Hankenson KD, Uusitalo H, Hiltunen A, Gardner H, Heino J, Penttinen R. Diminished callus size and cartilage synthesis in alpha 1 beta 1 integrin-defi-cient mice during bone fracture healing. Am J Pathol. 2002;160(5):1779-85.
73. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem. 1999;274(13):8925-32.
74. Werb Z, Chin JR. Extracellular matrix remodeling during morphogenesis. Ann N Y Acad Sci. 1998;857:110-8.
75. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem. 1993;53(4):288-95.
76. Marsh D. Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat Res. 1998;(355 Suppl):S22-30.
77. Weber BG, Cech O. Pseudarthrosen: pathophysiologie, biomechanik, therapie, ergebnisse. Bern, Switzerland: Verlag Hans Huber; 1973.
78. Segmuller G, Cech O, Bekier A. [Osteogenic activity in the area of pseudarthrosis of the long tubular bones]. Z Orthop Ihre Grenzgeb. 1969;106(3):599-609.
79. Reed AA, Joyner CJ, Isefuku S, Brownlow HC, Simpson AH. Vascularity in a new model of atrophic nonunion. J Bone Joint Surg Br. 2003;85(4):604-10.
80. Hietaniemi K, Lehto MU, Paavolainen P. Major fibril-lar collagens and fibronectin in an experimental nonunion: an immunohistochemical study. Acta Orthop Scand. 1998;69(5):545-9.
81. Brick KE, Chen X, Lohr J, Schmidt AH, Kidder LS, Lew WD. rhBMP-2 modulation of gene expression in infected segmental bone defects. Clin Orthop Relat Res. 2009;467(12):3096-103.
82. Lawton DM, Andrew JG, Marsh DR, Hoyland JA, Free-mont AJ. Expression of the gene encoding the matrix gla protein by mature osteoblasts in human fracture non-unions. Mol Pathol. 1999;52(2):92-6.
83. Lawton DM, Andrew JG, Marsh DR, Hoyland JA, Free-mont AJ. Mature osteoblasts in human non-union fractures express collagen type III. Mol Pathol. 1997;50(4):194-7.
84. Paralkar VM, Weeks BS, Yu YM, Kleinman HK, Reddi AH. Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: poten-tiation and binding to type IV collagen. J Cell Biol. 1992;119(6):1721-8.
85. Herrmann M, Klitscher D, Georg T, Frank J, Marzi I, Herrmann W. Different kinetics of bone markers in normal and delayed fracture healing of long bones. Clin Chem. 2002;48(12):2263-6.
86. Henle P, Zimmermann G, Weiss S. Matrix metalloprotein-ases and failed fracture healing. Bone. 2005;37(6):791-8.
87. Buttaro MA, Gonzalez Della Valle AM, Pineiro L, Mocetti E, Morandi AA, Piccaluga F. Incorporation of vancomy-cin-supplemented bone incorporation of vancomycin-sup-plemented bone allografts: radiographical, histopathologi-cal and immunohistochemical study in pigs. Acta Orthop Scand. 2003;74(5):505-13.
88. Waters RV, Gamradt SC, Asnis P, Vickery BH, Avnur Z, Hill E, Bostrom M. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. Acta Orthop Scand. 2000;71(3):316-21.
89. Iu MF, Kaji H, Sowa H, Naito J, Sugimoto T, Chihara K. Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol. 2005;185(1):131-8.
90. Nagel T, Kelly DJ. Mechano-regulation of mesenchymal stem cell differentiation and collagen organisation during skeletal tissue repair. Biomech Model Mechanobiol. 2010;9(3):359-72.
91. Rothem DE, Rothem L, Soudry M, Dahan A, Eliakim R. Nicotine modulates bone metabolism-associated gene expression in osteoblast cells. J Bone Miner Metab. 2009;27(5):555-61.
92. Einhorn TA, Gundberg CM, Devlin VJ, Warman J. Fracture healing and osteocalcin metabolism in vitamin K deficiency. Clin Orthop Relat Res. 1988;(237):219-25.
93. Oni OO, Mahabir JP, Iqbal SJ, Gregg PJ. Serum osteocal-cin and total alkaline phosphatase levels as prognostic indicators in tibial shaft fractures. Injury. 1989;20(1):37-8.
94. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL. Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest. 1983;71(5):1316-21.
95. Jones ED. Effects of local alkaline phosphatase in experimentally produced fracture in the rabbit. Am J Surg. 1951;81(4):417-20.
96. Sieber E. [The significance of alkaline serum phosphatase analysis in the course of bone fracture healing.]. Zentralbl Chir. 1953;78(37):1583-90.
97. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(Suppl 6):S2-17.
98. Adami S, Gatti D, Viapiana O, Fiore CE, Nuti R, Luisetto G, Ponte M, Rossini M. Physical activity and bone turnover markers: a cross-sectional and a longitudinal study. Calcif Tissue Int. 2008;83(6):388-92.
99. Seebeck P, Bail HJ, Exner C, Schell H, Michel R, Amthauer H, Bragulla H, Duda GN. Do serological tissue turnover markers represent callus formation during fracture healing? Bone. 2005;37(5):669-77.
100. Gothlin G, Ericsson JL. Fine structural localization of alkaline phosphatase in the fracture callus of the rat. Histo-chemie. 1973;36(3):225-36.
101. Felix R, Herrmann W, Fleisch H. Stimulation of precipitation of calcium phosphate by matrix vesicles. Biochem J. 1978;170(3):681-91.
102. Anderson HC, Stechschulte DJ Jr, Collins DE, Jacobs DH, Morris DC, Hsu HH, Redford PA, Zeiger S. Matrix vesicle biogenesis in vitro by rachitic and normal rat chondro-cytes. Am J Pathol. 1990;136(2):391-8.
103. Moss DW. Alkaline phosphatase isoenzymes. Clin Chem. 1982;28(10):2007-16.
104. Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta. 1990;186(2):315-20.
105. Posen S, Grunstein HS. Turnover rate of skeletal alkaline phosphatase in humans. Clin Chem. 1982;28(1):153-4.
106. Denney JD, Sherrard DJ, Nelp WB, Chesnut CH 3rd, Baylink DJ. Total body calcium and long-term calcium balance in chronic renal disease. J Lab Clin Med. 1973;82(2):226-40.
107. Manolagas SC, Spiess YH, Burton DW, Deftos LJ. Mechanism of action of 1,25-dihydroxyvitamin D3-induced stimulation of alkaline phosphatase in cultured osteoblast-like cells. Mol Cell Endocrinol. 1983;33(1):27-36.
108. Manolagas SC, Burton DW, Deftos LJ. 1,25-Dihydroxyvi-tamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem. 1981;256(14):7115-7.
109. Duda RJ, Jr., Kumar R, Nelson KI, Zinsmeister AR, Mann KG, Riggs BL. 1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic post-menopausal women. J Clin Invest. 1987;79(4):1249-53.
110. Hammett-Stabler CA. The use of biochemical markers in osteoporosis. Clin Lab Med. 2004;24(1):175-97.
111. Han B, Copeland M, Geiser AG, Hale LV, Harvey A, Ma YL, Powers CS, Sato M, You J, Hale JE. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propep-tide (PINP) to measure bone formation activity. J Proteome Res. 2007;6(11):4218-29.
112. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-termi-nal propeptide of human type I procollagen. Clin Chem. 1996;42(6 Pt 1):947-54.
113. Fleischmajer R, Perlish JS, Burgeson RE, Shaikh-Bahai F, Timpl R. Type I and type III collagen interactions during fibrillogenesis. Ann N Y Acad Sci. 1990;580:161-75.
114. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrod B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med. 1994;179(2):405-12.
115. Hale LV, Galvin RJ, Risteli J, Ma YL, Harvey AK, Yang X, Cain RL, Zeng Q, Frolik CA, Sato M, Schmidt AL, Geiser AG. PINP: a serum biomarker of bone formation in the rat. Bone. 2007;40(4):1103-9.
116. Harrison CA, Gossiel F, Bullock AJ, Sun T, Blumsohn A, Mac Neil S. Investigation of keratinocyte regulation of collagen I synthesis by dermal fibroblasts in a simple in vitro model. Br J Dermatol. 2006;154(3):401-10.
117. Burnett-Bowie SA, Saag K, Sebba A, de Papp AE, Chen E, Rosenberg E, Greenspan SL. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab. 2009;94(4):1097-103.
118. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20(6):962-70.
119. Claudon A, Vergnaud P, Valverde C, Mayr A, Klause U, Garnero P. New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem. 2008;54(9):1554-63.
120. Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone. 2006;39(2):237-43.
121. Denk E, Hillegonds D, Hurrell RF, Vogel J, Fattinger K, Hauselmann HJ, Kraenzlin M, Walczyk T. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. J Bone Miner Res. 2007;22(10):1518-25.
122. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R. Response rate of bone mineral density to teripara-tide in postmenopausal women with osteoporosis. Bone. 2006;39(6):1268-75.
123. Komi J, Lankinen KS, DeGregorio M, Heikkinen J, Saa-rikoski S, Tuppurainen M, Halonen K, Lammintausta R, Vaananen K, Ylikorkala O, Erkkola R. Effects of ospe-mifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24(4):314-8.
124. Nakatsuka K, Nishizawa Y, Miura M. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement of PICP and PINP in the evaluation of pharmaceutical treatment efficacy for osteoporosis]. Clin Calcium. 2006;16(6):977-85.
125. Watts NB, Miller PD, Kohlmeier LA, Sebba A, Chen P, Wong M, Krohn K. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res. 2009;24(6):1125-31.
126. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with al-endronate. Bone. 2007;41(1):122-8.
127. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18(1):59-68.
128. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006;21(2):292-9.
129. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20(11):1905-11.
130. Rissanen JP, Suominen MI, Peng Z, Morko J, Rasi S, Ri-steli J, Halleen JM. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int. 2008;82(2):155-61.
131. Delmas PD. Biochemical markers of bone turnover in Paget's disease of bone. J Bone Miner Res. 1999;14(Suppl 2):66-9.
132. Alvarez L, Peris P, Guanabens N, Vidal S, Quinto L, Mon-egal A, Pons F, Ballesta AM, Munoz-Gomez J. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology (Oxford). 2004;43(7):869-74.
133. Alvarez L, Guanabens N, Peris P, Vidal S, Ros I, Mon-egal A, Bedini JL, Deulofeu R, Pons F, Munoz-Gomez J, Ballesta AM. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone. 2001;29(5):447-52.
134. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate. 2009;69(6):624-32.
135. Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergstrom B. Oral ibandronate is as active as intravenous zoledron-ic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol. 2007;18(7):1165-71.
136. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmen-opausal women. Breast Cancer Res. 2007;9(4):R52.
137. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004;111(5):783-91.
138. Oremek G, Sauer-Eppel H, Klepzig M. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res. 2007;27(4A):1961-2.
139. Joerring S, Jensen LT. Changes in collagen metabolites in serum after cemented hip and knee arthroplasty. Arch Orthop Trauma Surg. 1993;112(3):139-41.
140. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993;8(2):127-32.
141. Celeste AJ, Rosen V, Buecker JL, Kriz R, Wang EA, Wozney JM. Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones. EMBO J. 1986;5(8):1885-90.
142. Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Bio-phys Res Commun. 1983;117(3):765-71.
143. Price PA, Nishimoto SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci U S A. 1980;77(4):2234-8.
144. Ivaska KK, Hentunen TA, Vaaraniemi J, Ylipahkala H, Pet-tersson K, Vaananen HK. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem. 2004;279(18):18361-9.
145. Price PA, Williamson MK, Lothringer JW. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981;256(24):12760-6.
146. Delmas PD, Wilson DM, Mann KG, Riggs BL. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab. 1983;57(5):1028-30.
147. Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab. 1985;60(4):736-9.
148. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26(4):97-122.
149. Pedersen BJ, Schlemmer A, Hassager C, Christiansen C. Changes in the carboxyl-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest. Bone. 1995;17(1):91-5.
150. Lian J, Stewart C, Puchacz E, Mackowiak S, Shalhoub V, Collart D, Zambetti G, Stein G. Structure of the rat osteo-calcin gene and regulation of vitamin D-dependent expression. Proc Natl Acad Sci U S A. 1989;86(4):1143-7.
151. Schwab AM, Granholm S, Persson E, Wilkes B, Lerner UH, Conaway HH. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology. 2005;146(10):4349-61.
152. Fraser JD, Price PA. Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells. Calcif Tissue Int. 1990;46(4):270-9.
153. Herrmann M, Muller M, Scharhag J, Sand-Hill M, Kindermann W, Herrmann W. The effect of endurance exercise-induced lactacidosis on biochemical markers of bone turnover. Clin Chem Lab Med. 2007;45(10):1381-9.
154. Thompson Z, Miclau T, Hu D, Helms JA. A model for in-tramembranous ossification during fracture healing. J Orthop Res. 2002;20(5):1091-8.
155. Uusitalo H, Rantakokko J, Ahonen M, Jamsa T, Tuukkanen J, KaHari V, Vuorio E, Aro HT. A metaphyseal defect model of the femur for studies of murine bone healing. Bone. 2001;28(4):423-9.
156. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioim-munoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. 1980;66(5):878-83.
157. Dias IR, Viegas CA, de Azevedo JT, Costa EM, Lourenco P, Rodrigues A, Cabrita AS. Assessment of markers of bone formation under controlled environmental factors and their correlation with serum minerals in adult sheep as a model for orthopaedic research. Lab Anim. 2008;42(4):465-72.
158. Nyman MT, Paavolainen P, Forsius S, Lamberg-Allardt C. Clinical evaluation of fracture healing by serum os-teocalcin and alkaline phosphatase. Ann Chir Gynaecol. 1991;80(3):289-93.
159. Kurdy NM. Serology of abnormal fracture healing: the role of PIIINP, PICP, and BsALP. J Orthop Trauma. 2000;14(1):48-53.
160. Lotz J, Gaertner T, Hahn M, Prellwitz W. Collagen type I metabolism after bone surgery. Arch Orthop Trauma Surg. 1999;119(3-4):212-6.
161. Kurdy NM, Bowles S, Marsh DR, Davies A, France M. Serology of collagen types I and III in normal healing of tibial shaft fractures. J Orthop Trauma. 1998;12(2):122-6.
162. Joerring S, Krogsgaard M, Wilbek H, Jensen LT. Collagen turnover after tibial fractures. Arch Orthop Trauma Surg. 1994;113(6):334-6.
163. Obrant KJ, Merle B, Bejui J, Delmas PD. Serum bone-gla protein after fracture. Clin Orthop Relat Res. 1990;(258):300-3.
164. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem. 2008;54(1):188-96.
165. Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. 2007;22(8):1155-64.
166. Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following ankle fracture. Os-teoporos Int. 1999;10(5):408-15.
167. Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int. 1999;10(5):399-407.
168. Christensen B, Dyrberg E, Aagaard P, Enehjelm S, Krogs-gaard M, Kjaer M, Langberg H. Effects of long-term immobilization and recovery on human triceps surae and collagen turnover in the Achilles tendon in patients with healing ankle fracture. J Appl Physiol. 2008;105(2):420-6.
169. Komatsu DE, Brune KA, Liu H, Schmidt AL, Han B, Zeng QQ, Yang X, Nunes JS, Lu Y, Geiser AG, Ma YL, Wolos JA, Westmore MS, Sato M. Longitudinal in vivo analysis of the region-specific efficacy of parathyroid hormone in a rat cortical defect model. Endocrinology. 2009;150(4):1570-9.
170. Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eas-tell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int. 2006;17(3):364-72.
171. Chevrel G, Limouzin A, Garnero P, de Montalivet C, Lou-bier D. Fractures and handicap in an adult population: A clinical study. Joint Bone Spine. 2007;74(6):584-9.
172. Zanker CL, Swaine IL. Responses of bone turnover markers to repeated endurance running in humans under conditions of energy balance or energy restriction. Eur J Appl Physiol. 2000;83(4 -5):434-40.
173. Crameri RM, Langberg H, Teisner B, Magnusson P, Schroder HD, Olesen JL, Jensen CH, Koskinen S, Suetta C, Kjaer M. Enhanced procollagen processing in skeletal muscle after a single bout of eccentric loading in humans. Matrix Biol. 2004;23(4):259-64.
174. Haining SA, Atkins RM, Guilland-Cumming DF, Sharrard WJ, Russell RG, Kanis JA. Vitamin D metabolites in patients with established non-union of fracture. Bone Miner. 1986;1(3):205-9.
175. Southwood LL, Frisbie DD, Kawcak CE, McIlwraith CW. Evaluation of serum biochemical markers of bone metabolism for early diagnosis of nonunion and infected nonunion fractures in rabbits. Am J Vet Res. 2003;64(6):727-35.
176. Gineyts E, Cloos PA, Borel O, Grimaud L, Delmas PD, Garnero P. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem J. 2000;345(Pt 3):481-5.